Biotech | May 12, 2022
First patient dosed with antiepileptic drug candidate CB03 in a first-in-human Phase I trial
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Survey findings released in advance of World Lupus Day on May 10
The demand for high-quality paediatric medicines has been growing rapidly in China as a result of the government’s support and policy measures
Parkinson’s is not limited to old people, even youngsters can suffer from this disease
Ind-Ra expects FY22 IPM to have witnessed 15% YoY sales growth, higher than the 8%-10% observed over the past five years, aided by the base effect
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Alongside brand refresh, the leading clinical trial technology company announces eConsent and eCOA offerings to better support the patient clinical trial journey
Subscribe To Our Newsletter & Stay Updated
